New asthma drug JYB1904 shows promise in early trial

NCT ID NCT06438757

Completed Disease control Sponsor: Jemincare Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug, JYB1904, in 69 adults with allergic asthma. Participants received either JYB1904 every 8 weeks or the standard drug omalizumab every 2 to 4 weeks for 24 weeks. The goal was to see how the drug behaves in the body, how safe it is, and how well it controls asthma symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JYB1904 (a biologic drug targeting IgE, similar to omalizumab)
What this could lead to: If successful, JYB1904 could offer a new treatment option for allergic asthma, potentially requiring fewer injections than current therapies.
What could go wrong: This is an early Phase IIa trial with only 69 participants, so results may not confirm effectiveness or safety. The drug may not work better than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC ASTHMA

Contacts and locations

Locations

Shanghai General Hospital

Shanghai, Shanghai Municipality, 201203, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.